Erratum: Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: Open-label pilot study for assessing the efficacy, tolerability and impact on quality of life (J Neurooncol DOI:10.1007/s11060-011-0689-z);Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: Open-label pilot study for assessing the efficacy, tolerability and impact on quality of life

Journal of Neuro-Oncology

Volumn 106, Issue 3, 2012, Pages 651-656

  Maschio, M ^a   Dinapoli, L ^a   Sperati, F ^a   Fabi, A ^a   Pace, A ^a   Vidiri, A ^a   Muti, P ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antiepileptic drugs; Brain tumor related epilepsy; Efficacy; Oxcarbazepine; Quality of life

Indexed keywords

OXCARBAZEPINE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; HUMAN; LUNG DISEASE; MALE; MONOTHERAPY; MOOD DISORDER; MULTIMODALITY CANCER THERAPY; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; PILOT STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; RASH; SEIZURE; SYSTEMIC THERAPY; TREATMENT DURATION;

EID: 84857059629     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0732-0     Document Type: Erratum

References (36)

1. Glantz MJ, Cole BF, Forsyth PA et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 54: 1886-1893
2. Pace A, Bove L, Innocenti P et al (1998) Epilepsy and glioma: incidence and treatment in 119 patients. J Exp Clin Cancer Res 17: 479-482 (Pubitemid 29083423)
3. Telfeian AE, Philips MF, Crino PB, Judy KD (2001) Postoperative epilepsy in patients undergoing craniotomy for glioblastoma multiforme. J Exp Clin Cancer Res 20: 5-10 (Pubitemid 32423966)
4. Glantz MJ, Recht LD (1997) Epilepsy in the cancer patient. In: Vecht CJ (ed) Handbook of clinical neurology, vol 65 (69). Neuro-oncology, part III. Elsevier, Netherlands, pp 9-16
5. Schaller B, Ruegg SJ (2003) Brain tumor and seizures: pathophysiology and its implications for treatment revised. Epilepsia 44: 1223-1232 (Pubitemid 37100049)
6. De Angelis L (2001) Brain tumors. N Engl J Med 344: 114-123 (Pubitemid 32052502)
7. Spina E, Perucca E (2002) Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43 (Suppl 2): 37-44 (Pubitemid 34229485)
8. Maschio M, Dinapoli L, Zarabla A, Jandolo B (2006) Issues related to the pharmacological management of patients with brain tumours and epilepsy. Funct Neurol 21: 15-19 (Pubitemid 43985840)
9. Taillibert S, Laigle-Donadey F, SansonM (2004) Palliative care in patients with primary brain tumors. Curr Opin Oncol 16: 587-592 (Pubitemid 39482979)
10. Vecht CJ, Van Breemen M (2006) Optimizing therapy of seizures in patients with brain tumors. Neurology 67 (12 Suppl 4): S10-13 (Pubitemid 44967990)
11. Mauro AM, Bomprezzi C, Morresi S et al (2007) Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. J Neurooncol 81: 279-285 (Pubitemid 46165332)
12. Maschio M, Dinapoli L, Zarabla A et al (2008) Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 86: 61-70 (Pubitemid 350263434)
13. Maschio M, Albani F, Baruzzi A et al (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 80: 97-100 (Pubitemid 44473268)
14. Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78: 99-102 (Pubitemid 43786667)
15. Novy J, Stupp R, Rossetti AO (2009) Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg 111: 171-173
16. Maschio M, Dinapoli L, Saveriano F et al (2009) Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. Acta Neurol Scand 120: 210-212
17. Wellington K, Goa KL (2001) Oxcarbazepine. An update of its efficacy in the management of epilepsy. CNS Drugs 15: 137-163 (Pubitemid 32197297)
18. Friis ML, Kristensen O, Boas J et al (1993) Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 87: 224-227 (Pubitemid 23089920)
19. Joca SR, Skalisz LL, Beijamini V, Vital MA, Andreatini R (2000) The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur Neuropsychopharmacol 10: 223-228 (Pubitemid 30394595)
20. Maschio M, Dinapoli L, Vidiri A et al (2009) The role side effects play in the choice of antiepileptic therapy in brain tumorrelated epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 6 28: 60
21. Baruzzi A, Albani F, Riva R (1994) Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 35: 14-19
22. Cancer therapy evaluation program, common terminology criteria for adverse events v4.0.http: //evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.02-2009-09-15- QuickReference-5x7.pdf
23. Christe W, Krämer G, Vigonius U et al (1997) A double-blind controlled clinical trial: oxarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 26: 451-460 (Pubitemid 27146303)
24. Dogan EA, Usta BE, Bilgen R, Senol Y, Aktekin B (2008) Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav 13: 156-161
25. Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, Muti P (2011) Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 104: 205-214
26. Beghi E, Perucca E (1995) The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research. Drugs 49: 680-694
27. Maschio M, Dinapoli L, Vidiri A, Muti P (2010) Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy. J Neurol 257 (11): 1939-1940
28. Mazza M, Della Marca G, Di Nicola M et al (2007) Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav 10: 397-401 (Pubitemid 46567766)
29. Sachdeo RC, Gates JR, Bazil CW et al (2006) Improved quality of life in patients with partial seizures after conversion to oxcarbazepine monotherapy. Epilepsy Behav 9: 457-463 (Pubitemid 44615633)
30. Pace A, Vidiri A, Galié E et al (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14: 1722-1726 (Pubitemid 38029042)
31. Ngo L, Nei M, Glass J (2006) Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia 47: 1237-1238 (Pubitemid 44086761)
32. Apolone G, Filiberti A, Cifani S, Ruggiata R, Mosconi P (1998) Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 health survey in a cohort of Italian long-survival cancer patients. Ann Oncol 9: 549-557 (Pubitemid 28270644)
33. Cramer JA, Van Hammée G, N132 Study Group (2003) Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epil Behav 2: 118-123 (Pubitemid 37184582)
34. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H (2004) Systematic screening allows reduction of adverse antiepileptic drug effects. A randomized trial. Neurology 62: 23-27 (Pubitemid 38082864)
35. Giovagnoli AR (1999) Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour. J Neurol Neurosurg Psych 67: 358-363 (Pubitemid 29392596)
36. Macdonald DR, Cascino TL, JR ScholdSC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280 (Pubitemid 20195640)